What is the 13F Pro Quality Score for TBPH?

13F Pro ranks Theravance Biopharma, Inc. (TBPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TBPH's current score at https://13fpro.ai/company/TBPH (free sign-up required for the full ranking).

Which hedge funds own the most TBPH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TBPH include Madison Avenue Partners,, Weiss Asset Management, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TBPH as soon as new 13F filings post.

Where does 13F Pro source TBPH data?

All Theravance Biopharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Theravance Biopharma, Inc. files with the SEC under CIK 1583107. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TBPH in?

Theravance Biopharma, Inc. (TBPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives TBPH's revenue?

Per Theravance Biopharma, Inc.'s latest 10-Q filed with the SEC on 2026-08-11, the biggest revenue drivers are: Viatris collaboration agreement ($20.7M, +11% YoY); Licensing and milestone revenue ($0, -100% YoY (NM)). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/TBPH.

What are TBPH's largest expenses?

Theravance Biopharma, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($14.2M, -23% YoY); Transaction-related expenses ($6.1M, NM (vs. $0 PY)); Research and development ($4.7M, -55% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is TBPH research updated on 13F Pro?

TBPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Theravance Biopharma, Inc.(TBPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1583107 TBPH stock profile & AI dashboard →

13F Pro Quality Score

69.2/100

Rank #280 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

87.6/100

Profitability

98.1/100

Balance Sheet

89.0/100

Earnings Quality

61.7/100

Free Cash Flow

95.4/100

Institutional Flow

7.9/100

Revenue Scale

16.4/100

Dilution Risk

10.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TBPH Scores 69/100

exact factor attribution · 2026-09-11

TBPH's composite is driven by revenue growth and profitability, held back by scale and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.5 pts

88th pct

Profitability

+7.2 pts

98th pct

Free cash flow

+6.8 pts

95th pct

Capital efficiency

+3.9 pts

89th pct

Earnings growth

+1.7 pts

84th pct

Earnings quality

+1.2 pts

62th pct

Shareholder dilution

-2.0 pts

10th pct

Institutional flow

-2.1 pts

8th pct

Scale

-5.0 pts

16th pct

Latest change (2026-08-11): 69 → 32 · ↓ Profit margin 95→18; ↓ Free cash flow 98→18

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in TBPH

Events flagged as statistical outliers against TBPH's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-11
TBPH quality score dropped 37 points (69→32) on a new filing
View source filing →

TBPH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Theravance Biopharma, Inc. (TBPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TBPH at 69.2/100 on a 32-signal composite quality model, placing it at rank #280 of 2,961 stocks — the top 10% of the AI-ranked universe. TBPH scores in the top quartile across profitability (98.1), free cash flow (95.4), balance sheet strength (89.0). Areas of concern include institutional flow (7.9) and revenue scale (16.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Theravance Biopharma, Inc. reports quarterly revenue of $20.7M, net income of $-5.9M. Top institutional holders of TBPH by reported 13-F value include Madison Avenue Partners, Weiss Asset Management, BlackRock, based on the most recent SEC filings. TBPH trades on the Nasdaq exchange and files with the SEC under CIK 1583107. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TBPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theravance Biopharma, Inc. directly from SEC EDGAR. Theravance Biopharma, Inc.'s 13F Pro composite quality score has ranged between 12 and 74 since 2021, currently 69.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

What's Driving TBPH's Business? Latest 10-Q Breakdown

✓ 16/16 datapoints verified

AI-extracted from Theravance Biopharma, Inc.'s 10-Q filed 2026-08-11 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Theravance reported Q2 FY2026 revenue of $20.7M (-21% YoY) as it agreed to be acquired by Zymeworks for $17.00/share cash plus a CVR, while winding down its failed ampreloxetine program.

Biggest Revenue Drivers

Viatris collaboration agreement$20.7M+11% YoY

Higher YUPELRI net sales, which grew 7% YoY driven by 10% customer demand growth

Licensing and milestone revenue$0-100% YoY (NM)

Prior-year quarter included a one-time $7.5M milestone from YUPELRI's China NMPA approval; no milestone this quarter

Biggest Revenue Drivers

Total revenue: $20.7M-21% YoY

Viatris collaboration agreement$20.7M+11% YoY

Higher YUPELRI net sales, which grew 7% YoY driven by 10% customer demand growth

Licensing and milestone revenue$0-100% YoY (NM)

Prior-year quarter included a one-time $7.5M milestone from YUPELRI's China NMPA approval; no milestone this quarter

Largest Expense Items

Selling, general and administrative$14.2M-23% YoY

Cost savings from the Restructuring and lower pre-commercial CYPRESS launch spend

Transaction-related expenses$6.1MNM (vs. $0 PY)

Legal and financial advisory costs related to the Zymeworks Merger Agreement

Research and development$4.7M-55% YoY

Lower employee-related and external costs from the Restructuring and CYPRESS wind-down

Restructuring expenses$4.0MNM (vs. $0 PY)

One-time severance and equity-award modification costs from the March 2026 workforce reduction

Margins: No gross margin is presented; R&D and SG&A fell 55% and 23% YoY on Restructuring savings, but new Restructuring and Merger transaction costs widened the operating loss to $8.3M from $2.7M a year ago.

Watch Items from the Filing

Theravance agreed to be acquired by Zymeworks for $17.00/share cash plus a contingent value right; close expected H2 2026, subject to shareholder and regulatory approval.
Ampreloxetine's Phase 3 CYPRESS study missed its primary endpoint in March 2026, triggering a wind-down and ~50% reduction of the 90-employee workforce.
Total revenue is entirely dependent on the single Viatris/YUPELRI collaboration, with no other commercial products contributing.
A $32.5M termination fee is payable to Zymeworks if the Merger Agreement is terminated under specified circumstances.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$20.7M

Net Income

Q2 2026

$-5.9M

ROIC

Q2 2026

-11.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+66.9% YoY

$107.5MFY 2025

FY22 $51.3MFY23 $57.4MFY24 $64.4MFY25 $107.5M

Net Income

+287.7% YoY

$105.9MFY 2025

FY22 $872.1MFY23 $-55.2MFY24 $-56.4MFY25 $105.9M

Operating Income

+92.3% YoY

$-3.6MFY 2025

FY22 $-92.0MFY23 $-56.0MFY24 $-46.9MFY25 $-3.6M

EPS (Diluted)

+279.1% YoY

$2.06FY 2025

FY22 $11.85FY23 $-1.00FY24 $-1.15FY25 $2.06

Total Assets

+37.1% YoY

$485.6MFY 2025

FY22 $607.4MFY23 $382.0MFY24 $354.2MFY25 $485.6M

Total Debt

—FY 2025

FY22 —FY23 $0.00FY24 —FY25 —

Op. Cash Flow

+2168.0% YoY

$238.5MFY 2025

FY22 $-187.0MFY23 $-27.0MFY24 $-11.5MFY25 $238.5M

Free Cash Flow

+2109.8% YoY

$238.5MFY 2025

FY22 $-187.6MFY23 $-29.5MFY24 $-11.9MFY25 $238.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$107.5M +66.9%	$64.4M +12.1%	$57.4M +11.8%	$51.3M -7.2%	$55.3M -23.0%	$71.9M
Net Income	$105.9M +287.7%	$-56.4M -2.2%	$-55.2M -106.3%	$872.1M +537.3%	$-199.4M +28.3%	$-278.0M
Operating Income	$-3.6M +92.3%	$-46.9M +16.2%	$-56.0M +39.1%	$-92.0M +64.3%	$-257.8M +13.4%	$-297.6M
EPS (Diluted)	$2.06 +279.1%	$-1.15 -15.0%	$-1.00 -108.4%	$11.85 +512.9%	$-2.87 +35.7%	$-4.46
Total Assets	$485.6M +37.1%	$354.2M -7.3%	$382.0M -37.1%	$607.4M +62.1%	$374.8M -20.1%	$469.1M
Total Debt	—	—	$0.00	—	$616.3M -0.5%	$619.2M
Operating Cash Flow	$238.5M +2168.0%	$-11.5M +57.3%	$-27.0M +85.6%	$-187.0M +10.0%	$-207.9M +17.0%	$-250.4M
Free Cash Flow	$238.5M +2109.8%	$-11.9M +59.8%	$-29.5M +84.3%	$-187.6M +11.2%	$-211.3M +17.8%	$-257.0M

Get alerted when TBPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Theravance Biopharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TBPH

Madison Avenue Partners, LP
$156.6M9,212,252 sh
Weiss Asset Management LP
$126.8M7,457,060 sh
BlackRock, Inc.
$77.6M4,562,487 sh
Newtyn Management, LLC
$58.4M3,434,191 sh
Irenic Capital Management LP
$46.9M2,760,948 sh
VANGUARD CAPITAL MANAGEMENT LLC
$30.1M1,771,493 sh
STATE STREET CORP
$22.6M1,328,584 sh
TWO SIGMA INVESTMENTS, LP
$20.8M1,225,587 sh
D. E. Shaw & Co., Inc.
$20.2M1,185,390 sh
ACADIAN ASSET MANAGEMENT LLC
$20.0M1,174,910 sh

Fund	Value	Shares
Madison Avenue Partners, LP	$156.6M	9,212,252
Weiss Asset Management LP	$126.8M	7,457,060
BlackRock, Inc.	$77.6M	4,562,487
Newtyn Management, LLC	$58.4M	3,434,191
Irenic Capital Management LP	$46.9M	2,760,948
VANGUARD CAPITAL MANAGEMENT LLC	$30.1M	1,771,493
STATE STREET CORP	$22.6M	1,328,584
TWO SIGMA INVESTMENTS, LP	$20.8M	1,225,587
D. E. Shaw & Co., Inc.	$20.2M	1,185,390
ACADIAN ASSET MANAGEMENT LLC	$20.0M	1,174,910

Companies Similar to TBPH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile · 12 shared holders

CWA Asset Management Group, LLC MARTINGALE ASSET MANAGEMENT L P Virtus Investment Advisers, LLC

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 14 shared holders

Weiss Asset Management LP CWA Asset Management Group, LLC WEDGE CAPITAL MANAGEMENT L L P/NC

INVA

Innoviva, Inc.

AI score

Similar quality profile · 13 shared holders

MARTINGALE ASSET MANAGEMENT L P SEGALL BRYANT & HAMILL, LLC Susquehanna Portfolio Strategies, LLC

COLL

COLLEGIUM PHARMACEUTICAL, INC

AI score

Similar quality profile · 10 shared holders

WEDGE CAPITAL MANAGEMENT L L P/NC MARTINGALE ASSET MANAGEMENT L P Jackson Creek Investment Advisors LLC

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile · 5 shared holders

AVIVA PLC GLOBEFLEX CAPITAL L P MARTINGALE ASSET MANAGEMENT L P

VCEL

Vericel Corp

AI score

Similar quality profile · 12 shared holders

MARTINGALE ASSET MANAGEMENT L P SEGALL BRYANT & HAMILL, LLC Jackson Creek Investment Advisors LLC

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 3 shared holders

WEDGE CAPITAL MANAGEMENT L L P/NC SEGALL BRYANT & HAMILL, LLC Susquehanna Portfolio Strategies, LLC

RIGL

RIGEL PHARMACEUTICALS INC

AI score

Similar quality profile · 7 shared holders

Virtus Investment Advisers, LLC SIERRA SUMMIT ADVISORS LLC SEGALL BRYANT & HAMILL, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TBPH on your watchlist

Track score changes the day Theravance Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TBPH a good stock to buy?

13F Pro's AI-powered analysis of Theravance Biopharma, Inc. (TBPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TBPH are available on the TBPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TBPH is classified as a small company.

Which hedge funds own TBPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TBPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Theravance Biopharma, Inc.'s investment landscape.